Foamix Pharmaceuticals (NASDAQ: FOMX) shares have been on a free fall for the past six months, declining by more than 30 percent to $2.3. The clinical-stage company which develops and commercializes … [Read more...] about Foamix Pharmaceuticals: A dermatology play with more than 100% upside potential
Source: MS Money Moves Stocks closed higher last week in anticipation of the Fed to cut interest rates for the first time since the 2008 financial crisis. While this is welcomed by investors we … [Read more...] about Biopharma Stock Watch July 29th-August 2nd
The previous earnings report from Verastem (VSTM) was filled with volatility and surprises. As I outlined in my last piece, Verastem's Earnings - Is It a Buy Now?, Verastem is a company filled with … [Read more...] about Another Quarter of Growth for Verastem…Is It Enough?
On Wednesday June 12th, 2019 the MS Money Moves executive team spoke over the phone with Trevena Inc. (Nasdaq: TRVN). On the call was Trevena's President and Chief Executive Officer Carrie Bourdow … [Read more...] about Trevena Inc: A Budding Innovator Rooted In A Nobel Prize Winning Discovery
Source: MS Money Moves Week over week we see a slight improvement in the performance of the healthcare sector (represented as the XLV) and biotech industry (represented as the XBI) compared to the … [Read more...] about Biopharma Stock Watch July 22nd-26th, 2019
Biotechnology stocks have delivered massive returns over the last few years. Apart from improving the lives of patients, newly developed drugs have made big profits for investors in the process. A … [Read more...] about Aurinia Pharmaceuticals (NASDAQ: AUPH): Highly undervalued in light of Voclosporin’s blockbuster potential
Source: MS Money Moves July 8th-12th the Healthcare sector underperformed the greater markets as evident by the XLV and the IBB closing down -.66% and -2.06%, respectfully. The XBI stayed … [Read more...] about Biopharma Stock Watch July 15th-19th
Previously, our Chief Operating Officer Sultan Beardsley outlined an investment thesis for RegenXBio. This detailed report can be read here: Could This Biotech Stock Get Bought For $5.5 Billion? … [Read more...] about An Update on RegenXBio
After a recent selloff in mid June 2019, Stock price went from from $6.70 down to $3.44. Calithera Bio-sciences (Nasdaq: CALA) looks to have established a double bottom. New strong uptrend suggests it … [Read more...] about CALITHERA Initiates & Potential Buying Opportunity
EYPT | Range bound by follow_the_money on TradingView.com Long-Term pattern suggests that after previous dilution, Eyepoint Pharmaceuticals (Nasdaq: EYPT) stock price went range bound for quite … [Read more...] about Eyepoint’s Range Bound, Swing Opportunity?